CN113712193A - 修复皮肤系统的组合物制备方法及其用途 - Google Patents
修复皮肤系统的组合物制备方法及其用途 Download PDFInfo
- Publication number
- CN113712193A CN113712193A CN202010447931.1A CN202010447931A CN113712193A CN 113712193 A CN113712193 A CN 113712193A CN 202010447931 A CN202010447931 A CN 202010447931A CN 113712193 A CN113712193 A CN 113712193A
- Authority
- CN
- China
- Prior art keywords
- skin
- composition
- nicotinamide
- derivatives
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 26
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 claims abstract description 20
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 claims abstract description 20
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 19
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 19
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 19
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 19
- 229940016667 resveratrol Drugs 0.000 claims abstract description 19
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- BJHIKXHVCXFQLS-PUFIMZNGSA-N D-psicose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PUFIMZNGSA-N 0.000 claims abstract description 14
- 238000005469 granulation Methods 0.000 claims abstract description 10
- 230000003179 granulation Effects 0.000 claims abstract description 10
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 9
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 9
- 239000011570 nicotinamide Substances 0.000 claims abstract description 9
- 230000037303 wrinkles Effects 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 4
- 230000009759 skin aging Effects 0.000 claims abstract description 4
- 230000001737 promoting effect Effects 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims description 24
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 16
- 229960002663 thioctic acid Drugs 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 238000004806 packaging method and process Methods 0.000 claims description 8
- 238000005507 spraying Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims description 7
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 229950006238 nadide Drugs 0.000 claims description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 3
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 230000037075 skin appearance Effects 0.000 claims description 2
- FQWLMRXWKZGLFI-YVYUXZJTSA-N (-)-trans-epsilon-viniferin Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC2=C1[C@@H](C=1C=C(O)C=C(O)C=1)[C@H](C=1C=CC(O)=CC=1)O2 FQWLMRXWKZGLFI-YVYUXZJTSA-N 0.000 claims 2
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 claims 1
- FQWLMRXWKZGLFI-UHFFFAOYSA-N cis epsilon-viniferine Natural products C1=CC(O)=CC=C1C=CC1=CC(O)=CC2=C1C(C=1C=C(O)C=C(O)C=1)C(C=1C=CC(O)=CC=1)O2 FQWLMRXWKZGLFI-UHFFFAOYSA-N 0.000 claims 1
- SXRAUGAFMDOHKN-UHFFFAOYSA-N epsilon-viniferin Natural products CC1(Oc2cc(O)cc(C=Cc3ccc(O)cc3)c2C1(C)c4cc(O)cc(O)c4)c5ccc(O)cc5 SXRAUGAFMDOHKN-UHFFFAOYSA-N 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 36
- 239000008187 granular material Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000008569 process Effects 0.000 description 8
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000750718 Pterocarpus santalinus Species 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000020956 nicotinamide riboside Nutrition 0.000 description 2
- 239000011618 nicotinamide riboside Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000004824 Trimezia steyermarkii Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000009136 dragon's blood Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000001613 integumentary system Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- -1 stilbene compound Chemical class 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供了一种用于修复皮肤系统的组合物制备方法及其组合物的用途。组合物主要由D‑阿洛酮糖、硫辛酸类、烟酰胺及衍生物、白黎芦醇类及其衍生物(如紫檀芪)组成的制剂,该制剂包括但不限于以药品、食品、化妆品形式上市。制备方法为:采用流化床一步造粒法。组合物的用途为修复皮肤系统主要包括皮肤色斑、皱纹、干燥、粗糙等,促进和改善皮肤外观,延缓肌肤衰老。
Description
技术领域
本发明涉及医药、食品技术领域,具体涉及一种修复皮肤系统的组合物制备方法及其组合物的用途。
背景技术
皮肤系统(integumentary system):人体11大功能系统之一,皮肤系统由皮肤构成,包围在人体的外表面,起着保护身体不受外物侵害,保持体内环境稳定性的作用。皮肤是躯体的防水层,他保护躯体,防止躯体脱水。皮肤还是感受器官,对触摸、压力、温寒和疼痛很敏感。皮肤还有毛发,可以保温和保护皮肤。
皮肤衰老会在你的脸上留下什么。
当皮肤开始衰老的时候,在脸部的呈现最为明显。首先,你会发现原本白皙的肤色变得越来越暗黄,皮肤再也不如原来那样水润光滑,而是变得干燥、粗糙、毛孔粗大,甚至还会有一些色斑的光顾,肤质越来越差。其次,你还会发现面部轮廓开始塌陷,太阳穴和苹果肌已经不再饱满,皮肤越来越松弛下垂,很多原本是做表情才会出现的动态皱纹,也变成随时随地都会出现的静态皱纹,鼻唇沟和泪沟等一些衰老标志性皱纹也出现在了脸上。嘴唇也渐渐不再饱满,眼角和口角也开始下垂,口角线明显,失去往日神采,衰老在脸上展现的淋漓尽致。
不再年轻的原因到底是什么,人体皮肤是由表皮、真皮、皮下组织三部分组成,真皮层75%都是由胶原蛋白构成,其独特的网状结构保障了皮肤的弹性和张力,使皮肤呈现年轻化,皮肤的抗皱和保湿与胶原蛋白密切相关。皮下组织由大量的脂肪和结缔组织组成,皮下脂肪含量丰富会使皮肤显得紧致、饱满、细腻。然而岁月在流逝,一起流逝的还有你皮肤中的胶原蛋白和皮下脂肪,皮肤的韧性和弹性会随之降低,再加上地心引力的作用,脸部皮肤会变得下垂;而且皮肤组织中成分缺失不足,会使皮肤组织容积减少,面部轮廓就会出现松驰塌陷,皱纹也会随之出现。
阿洛酮糖是葡萄干、无花果、小麦等自然界中微量存在的糖份,每克热量仅为0~0.2kcal。味道像砂糖一样纯粹,热量却是砂糖(4kcal/g)的5%。作为甜味剂与蔗糖、果糖等混合使用,可大幅度降低热量,有望代替果糖。
阿洛酮糖还具有减少体脂肪的效果,在调节体重或血糖管理方面将受到现代人的青睐。
硫辛酸 (alpha lipoic acid) 是一种存在于线粒体的辅酶,类似维他命,能消除加速老化与致病的自由基。硫辛酸在体内经肠道吸收后进入细胞,兼具脂溶性与水溶性的特性,因此可以在全身通行无阻,到达任何一个细胞部位,提供人体全面效能,是具脂溶性与水溶性的万能抗氧化剂。
此前一些研究曾证实烟酰胺核糖可以有效地促进新陈代谢。2012年来自瑞士洛桑联邦理工学院等处的研究人员发现牛奶中的天然成分烟酰胺核糖能够对抗肥胖。相关成果公布在Cell Metabolism杂志上。2014年科学家们证实通过饮食补充烟酰胺核糖能够阻止小鼠肝癌发展,诱使肿瘤退缩。
白藜芦醇是通过抗自由基、抗氧化的作用来延缓衰老,虽然白藜芦醇具有很强的抗衰老作用,但由于其结构稳定性差,且在血液内滞留时间较短,故其单独应用受到限制。
紫檀芪是紫檀中所含的一种化学成分,但是科学家在其它植物中也相继发现了紫檀芪的存在,但因其首次发现与紫檀种,固命名为紫檀芪。紫檀芪为白色或类白色粉末结晶,有着丰富的药用价值,属于血竭制品中的抗真菌活性成分,对于癌症,高血压,高血脂的治疗都有一定的效果。日前,科研人员已经掌握了紫檀芪的工业合成方法。
紫檀芪是属多羟基二苯乙烯类化合物,为白藜芦醇的同系物,其药理作用除与白藜芦醇有部分相似之外,还具有较强的抗真菌活性(其抗真菌活性为白藜芦醇的五倍)。
流动床制粒是流化床制粒法是使药物粉末在自下而上的气流作用下保持悬浮的流化状态,粘合剂液体由上部或下部向流化室内喷入使粉末聚结成颗粒的方法。可在一台设备内完成沸腾混合、喷雾制粒、气流干燥的过程(也可包衣),又称一步制粒。与其它湿法制粒相比,具有工艺简单、操作时间短、劳动强度低等特点,而且减少物料搬运次数并缩短各工序所需时间,从而减少对物料和环境的污染。
发明内容
本发明的目的是克服现有技术的不足,给有皮肤系统有问题(包括衰老)的人士提供一个全新的产品。发明内容主要是包含三个方面:1、提供一种含有修复皮肤系统(包括衰老)的组合物。2、采用流化床一步制粒法制备。3、用于皮肤系统方面疾病的治疗和修复。
本发明提供一种含有修复皮肤系统(包括衰老)的组合物,组合物主要由D- 阿洛酮糖、硫辛酸类、烟酰胺及衍生物、白黎芦醇类及其衍生物(如紫檀芪)组成的制剂。
制剂做成包括但不限于以药品、食品(包括特殊医学用途食品、保健食品)。
制剂主要D- 阿洛酮糖、硫辛酸类、烟酰胺及衍生物、白黎芦醇类及其衍生物(如紫檀芪)组成,各组份如以下:
D- 阿洛酮糖 10至30份
硫辛酸类 1至10份
烟酰胺及衍生物 30至60份
白黎芦醇类及其衍生物(如紫檀芪) 5至20份
精确的组份如下:
D- 阿洛酮糖 20至25份
硫辛酸类 4至8份
烟酰胺及衍生物 40至50份
白黎芦醇类及其衍生物(如紫檀芪) 8至12份
更精确的组份如下:
D- 阿洛酮糖 25份
硫辛酸类 6份
烟酰胺及衍生物 50份
白黎芦醇类及其衍生物(如紫檀芪) 10份
该组合物的制备方法为:采用流化床一步造粒法。
具体的操作步骤为:
a、按处方量称取原辅料,混合均匀,得混合物1。
b、将混合物1放入流化床中,开启风机使粉末完全沸腾。
c、喷加粘合剂,制成大小适宜的颗粒。
d、开启加热,通过热风干燥。
e、水份合格后,停止加热,关闭风机,取出颗粒,检验合格,包装既得成品。
流动床制粒是流化床制粒法是使药物粉末在自下而上的气流作用下保持悬浮的流化状态,粘合剂液体由上部或下部向流化室内喷入使粉末聚结成颗粒的方法。可在一台设备内完成沸腾混合、喷雾制粒、气流干燥的过程(也可包衣),又称一步制粒。与其它湿法制粒相比,具有工艺简单、操作时间短、劳动强度低等特点,而且减少物料搬运次数并缩短各工序所需时间,从而减少对物料和环境的污染。
组合物制剂用途为修复皮肤系统主要包括皮肤色斑、皱纹、干燥、粗糙等,促进和改善皮肤外观,延缓肌肤衰老。
具体实施方式
实施例1
原辅料 | 用量(g) |
D- 阿洛酮糖 | 25 |
硫辛酸 | 6 |
烟酰胺腺嘌呤二核苷酸 | 50 |
白黎芦醇 | 10 |
辅料 | 4 |
共制成 | 1000片 |
操作步骤:
a、按处方量称取原辅料,混合均匀,得混合物1。
b、将混合物1放入流化床中,开启风机使粉末完全沸腾。
c、喷加粘合剂,制成大小适宜的颗粒。
d、开启加热,通过热风干燥,干燥温度为40至60℃。
e、水份合格后,停止加热,关闭风机,取出颗粒,检验合格,包装既得成品。
实施例2
原辅料 | 用量(g) |
D- 阿洛酮糖 | 30 |
硫辛酸 | 10 |
烟酰胺核糖 | 250 |
紫檀芪 | 50 |
辅料 | 60 |
共制成 | 1000片 |
操作步骤:
a、按处方量称取原辅料,混合均匀,得混合物1。
b、将混合物1放入流化床中,开启风机使粉末完全沸腾。
c、喷加粘合剂,制成大小适宜的颗粒。
d、开启加热,通过热风干燥,干燥温度为40至60℃。
e、水份合格后,停止加热,关闭风机,取出颗粒,检验合格,包装既得成品。
实施例3
原辅料 | 用量(g) |
D- 阿洛酮糖 | 50 |
硫辛酸 | 20 |
烟酰胺核糖 | 250 |
紫檀芪 | 50 |
辅料 | 60 |
共制成 | 1000片 |
操作步骤:
a、按处方量称取原辅料,混合均匀,得混合物1。
b、将混合物1放入流化床中,开启风机使粉末完全沸腾。
c、喷加粘合剂,制成大小适宜的颗粒。
d、开启加热,通过热风干燥,干燥温度为40至60℃。
e、水份合格后,停止加热,关闭风机,取出颗粒,检验合格,包装既得成品。
实施例4
原辅料 | 用量(g) |
D- 阿洛酮糖 | 40 |
硫辛酸 | 20 |
烟酰胺腺嘌呤二核苷酸 | 250 |
紫檀芪 | 50 |
辅料 | 60 |
共制成 | 1000片 |
操作步骤:
a、按处方量称取原辅料,混合均匀,得混合物1。
b、将混合物1放入流化床中,开启风机使粉末完全沸腾。
c、喷加粘合剂,制成大小适宜的颗粒。
d、开启加热,通过热风干燥,干燥温度为40至60℃。
e、水份合格后,停止加热,关闭风机,取出颗粒,检验合格,包装既得成品。
实施例5
原辅料 | 用量(g) |
D- 阿洛酮糖 | 40 |
硫辛酸 | 20 |
烟酰胺核糖 | 250 |
白黎芦醇 | 30 |
辅料 | 60 |
共制成 | 1000片 |
操作步骤:
a、按处方量称取原辅料,混合均匀,得混合物1。
b、将混合物1放入流化床中,开启风机使粉末完全沸腾。
c、喷加粘合剂,制成大小适宜的颗粒。
d、开启加热,通过热风干燥,干燥温度为40至60℃。
e、水份合格后,停止加热,关闭风机,取出颗粒,检验合格,包装既得成品。
实施例6
原辅料 | 用量(g) |
D- 阿洛酮糖 | 80 |
硫辛酸 | 20 |
烟酰胺单核苷酸 | 250 |
白黎芦醇 | 30 |
辅料 | 60 |
共制成 | 1000片 |
操作步骤:
a、按处方量称取原辅料,混合均匀,得混合物1。
b、将混合物1放入流化床中,开启风机使粉末完全沸腾。
c、喷加粘合剂,制成大小适宜的颗粒。
d、开启加热,通过热风干燥,干燥温度为40至60℃。
e、水份合格后,停止加热,关闭风机,取出颗粒,检验合格,包装既得成品。
实施例7:修复皮肤系统试验
将得到同意参加以下所述实验、且皮肤弹性及水分量低下的志愿者成年女性30名(35岁~ 55 岁,平均年龄 :48.6 岁),按 5 位 1 组分开,使各组分别口服各试料,将其持续6周。在口服试料前后用皮肤粘弹性测定装置对皮肤弹性进行测定,并且,对脸的预定部位的水分用水分测定装置测定水分相对值。需要说明的是,本实验以上述实施例样品而进行。口服量为 :每个样品一片,一天两次,连续服用。
该结果如下表 所示。试料口服前后的皮肤弹性及水分量是 :与口服前相比较,发现在口服后有明显改善作用,皮肤弹性及水分量明显得到改善,明确了根据本发明的组合物有明显血流改善剂作用、特别是有明显的修复皮肤系统作用。
表、实施例的皮肤弹性补水效果
实施例 | 弹性变化 | 水分变化 | |
1 | 5.6%±2.3% | 100.2% | |
2 | 6.9%±2.0% | 106.1% | |
3 | 7.1%±3.4% | 113.8% | |
4 | 5.2%±2.2% | 104.1% | |
5 | 4.9%±1.9% | 108.6% | |
6 | 6.5%±2.4% | 109.8% |
Claims (10)
1.本发明提供了一种用于修复皮肤系统的组合物制备方法及其用途。
2.组合物主要由烟酰胺及衍生物、白黎芦醇类及其衍生物(如紫檀芪)、D-阿洛酮糖、硫辛酸类组成的制剂,根据权利要求1所述的制剂,其特征是该制剂包括但不限于以药品、食品(包括特殊医学用途食品、保健食品)形式上市。
4.根据权利要求3所述的各主要成份范围如下:硫辛酸类主要包括硫辛酸和/或所述二氢硫辛酸为外消旋体;烟酰胺及衍生物是含有烟酰胺核糖、烟酰胺单核苷酸、烟酰胺腺嘌呤二核苷酸等;白藜芦醇类是含有从由白藜芦醇、ε-葡萄素、紫檀芪以及它们的异构体和/或配糖物组成的组群中选出的一种或两种以上的组合物;该组合物的制备方法为:采用流化床一步造粒法。具体的操作步骤为:
5.a、按处方量称取原辅料,混合均匀,得混合物1。
6.b、将混合物1放入流化床中,开启风机使粉末完全沸腾。
7.c、喷加粘合剂,制成大小适宜的颗粒。
8.d、开启加热,通过热风干燥。
9.e、水份合格后,停止加热,关闭风机,取出颗粒,检验合格,包装既得成品。
10.根据权利要求1至7所述的组合物制剂用途为修复皮肤系统主要包括皮肤色斑、皱纹、干燥、粗糙等,促进和改善皮肤外观,延缓肌肤衰老。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010447931.1A CN113712193A (zh) | 2020-05-25 | 2020-05-25 | 修复皮肤系统的组合物制备方法及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010447931.1A CN113712193A (zh) | 2020-05-25 | 2020-05-25 | 修复皮肤系统的组合物制备方法及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113712193A true CN113712193A (zh) | 2021-11-30 |
Family
ID=78671627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010447931.1A Pending CN113712193A (zh) | 2020-05-25 | 2020-05-25 | 修复皮肤系统的组合物制备方法及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113712193A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106955290A (zh) * | 2017-03-24 | 2017-07-18 | 南京顺昌医药科技有限公司 | 一种治疗退化性疾病的组合物及其用途 |
CN107849083A (zh) * | 2015-06-10 | 2018-03-27 | 益力舒健康公司 | 用于治疗皮肤病症的烟酰胺核苷和紫檀芪组合物和方法 |
-
2020
- 2020-05-25 CN CN202010447931.1A patent/CN113712193A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107849083A (zh) * | 2015-06-10 | 2018-03-27 | 益力舒健康公司 | 用于治疗皮肤病症的烟酰胺核苷和紫檀芪组合物和方法 |
CN106955290A (zh) * | 2017-03-24 | 2017-07-18 | 南京顺昌医药科技有限公司 | 一种治疗退化性疾病的组合物及其用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101116506B (zh) | 一种具有改善皮肤水分功能的保健品 | |
CN101828661B (zh) | 一种用于改善皮肤水分、除皱的保健食品 | |
CN102771869A (zh) | 一种胶原蛋白饮料制剂及其制备方法 | |
CN109222103A (zh) | 增肌组合物和保健食品 | |
CN109222100A (zh) | 一种人参蛹虫草组合物、人参蛹虫草压片糖果及其制备方法 | |
CN104605348A (zh) | 含有管花肉苁蓉提取物的保健品及其制备方法 | |
CN105250199A (zh) | 含珍珠粉的可食用面膜 | |
Takaoka et al. | Effect of amino-acid intake on physical conditions and skin state: a randomized, double-blind, placebo-controlled, crossover trial | |
CN113712193A (zh) | 修复皮肤系统的组合物制备方法及其用途 | |
TWI436787B (zh) | Glutathione production enhancers and pharmaceuticals, foods or cosmetics that promote the production of glutathione | |
KR101965594B1 (ko) | 콩 추출물을 포함하는 탈모 방지 또는 육모 촉진용 조성물 | |
CN105767718A (zh) | 一种具有祛黄褐斑功能的组合物及其制备方法 | |
CN107050143A (zh) | 一种具有改善睡眠功效的配方、组合物及其制备方法 | |
CN114403277A (zh) | 一种奶味解酒压片糖果及其制备方法 | |
CN113648347A (zh) | 含莲子外泌体的卵巢保养的组合物及其制备方法 | |
CN103082169A (zh) | 复合胶原果粉及其制法 | |
CN113304223A (zh) | 柔肝醒胃疏气活血宣通窒滞养颜活血收敛抗肿瘤的组合物 | |
CN105769659A (zh) | 食用胶原膜及其制备方法 | |
CN108323762B (zh) | 一种富硒组合物及制剂,其制备方法和应用 | |
CN106176510A (zh) | 一种用于美容保健的口服物及相应的美容保健组合物 | |
CN100404044C (zh) | 一种含鹿胎的祛黄褐斑药物和功能食品及其制备方法 | |
CN110679939A (zh) | 一种具有美容、美白、润肤和祛斑功能的食品组合物 | |
CN110585321A (zh) | 一种用于防治贫血的中药组合物及其制备方法与应用 | |
CN108355127A (zh) | 一种复合海洋鱼低聚肽胶囊及其制备方法 | |
CN102178020A (zh) | 猕猴桃咀嚼片配方及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211130 |
|
RJ01 | Rejection of invention patent application after publication |